Navigation Links
Renhuang Pharmaceuticals Receives Approval to List on the NYSE Amex
Date:7/1/2010

HARBIN, China, July 1 /PRNewswire-Asia-FirstCall/ -- Renhuang Pharmaceuticals, Inc. (Pink Sheets: RHGP) ("Renhuang" or the "Company"), a developer, manufacturer and distributor of botanical products, bio-pharmaceuticals and traditional Chinese medicines, today announced that the Company received approval to list its common stock on the NYSE Amex.

Renhuang expects to begin trading on the NYSE Amex on Friday, July 2, 2010. In connection with the listing on NYSE Amex, Renhuang's stock symbol will change to "CBP" from "RHGP".

"We are very pleased to move onto the NYSE Amex and begin our next phase as a public company," said Mr. Shaoming Li, Chairman of the Board, Chief Executive Officer and President of Renhuang Pharmaceuticals, Inc. "We are honored to join the family of NYSE companies and this is an important milestone in our continuous efforts to raise our profile within the investment community, improve our stock's liquidity, expand our transparency and enhance our corporate governance."

About Renhuang Pharmaceuticals, Inc.

Renhuang Pharmaceuticals, Inc. is engaged in the research, development, manufacturing, and distribution of botanical products, bio-pharmaceutical products, and TCM, in the People's Republic of China. All of the Company's products are produced at its three GMP-certified production facilities in Ah City, Dongfanghong and Qingyang. The Company distributes its botanical anti-depression and nerve-regulation products, biopharmaceutical products, and botanical antibiotic and OTC TCMs through its network of over 3,000 distributors and over 70 sales centers across 24 provinces in China. Company Website: http://www.renhuang.com .

Safe Harbor Statement

This press release contains certain statements that may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are based upon management's beliefs, assumptions and expectations of the Company's future operations and economic performance, taking into account the information currently available to management. These statements are not statements of historical fact. Forward-looking statements involve risks and uncertainties, some of which are not currently known that may cause actual results, performance or financial condition to be materially different from the expectations of future results, performance or financial condition expressed or implied in any forward-looking statements. These forward-looking statements are based on current plans and expectations and are subject to a number of uncertainties including, but not limited to, the Company's ability to achieve its financial guidance, perceived benefits of being listed on a senior stock exchange, ability to manage expansion of its operations effectively, competition in the marketing and sales of its products, and other factors detailed in the Company's annual report on Form 10-K and other filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented herein.

    For further information, please contact:

    Company Contact:
    Renhuang Pharmaceuticals, Inc.
     Ms. Portia Tan, IR Contact
     Tel:   +86-451-8260-2162
     Email: ir@renhuang.com

    CCG Investor Relations:
     Mr. Mark Collinson, Partner
     Phone: +1-310-954-1343 (Los Angeles)
     Email: mark.collinson@ccgir.com
     Web:   http://www.ccgirasia.com

     Mr. Crocker Coulson, President
     Phone: +1-646-213-1915 (New York)
     Email: crocker.coulson@ccgir.com


'/>"/>
SOURCE Renhuang Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Renhuang Announces Fiscal Year 2010 Guidance
2. Renhuang Announces Price Increase on Shengmai Granules
3. Renhuang Schedules Conference Call to Discuss FY 2010 First Quarter Results
4. Renhuang Pharmaceuticals Announces Continual Improvement in Days Sales Outstanding
5. Renhuang Appoints New Director and Establishes Nominating and Compensation Committee
6. Renhuang Pharmaceuticals Announces Plans to Introduce Qing Re Jie Du Oral Liquid
7. Renhuang Elected as Deputy Chair Unit of Heilongjiang Medical Association
8. Renhuang Pharmaceuticals Exhibits All-Natural Products at the 107th China Import and Export Fair
9. Renhuang Announces Successful Preliminary Review of Its Patent Application for Schisandra Total Lignin Extraction Method
10. Renhuang Appoints PricewaterhouseCoopers to Develop a SOX 404 Compliance Program
11. Renhuang Schedules Conference Call to Discuss FY 2010 Second Quarter Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/2/2016)... , May 2, 2016  While nearly three-quarters of ... can have on their health, only about half report ... to the results of a new survey announced today ... the start of National Osteoporosis Month, Hologic is raising ... affects nearly 56 million Americans. Osteoporosis is ...
(Date:4/29/2016)... April 29, 2016 ReportsnReports.com ... 2016" market research report that provides an overview ... analysis at various stages, therapeutics assessment by drug ... (RoA) and molecule type, along with latest updates, ... reviews key players involved in the therapeutic development ...
(Date:4/29/2016)... , April 29, 2016 ... life science laboratory due to the growing demands for ... advance technology, contemporary automated systems are already adept of ... by slow, tedious and manual labor. Instrumentation continues to ... not even conceivable just a few years ago. Originally ...
Breaking Medicine Technology:
(Date:5/3/2016)... ... May 03, 2016 , ... ... – a web application that helps people assess their risk of developing Alzheimer’s ... app will provide users a “Risk Reduction Score™” that summarizes how their lifestyle ...
(Date:5/3/2016)... Baltimore, Md. (PRWEB) , ... May 03, 2016 , ... ... devastating consequences of inappropriate or excessive levels of alcohol use. Alcohol and its ... fetal alcohol spectrum disorders to the susceptibility to strokes in those 65 years and ...
(Date:5/3/2016)... ... May 03, 2016 , ... SELEX (systematic evolution of ... a random library of sequences depending on their attraction for a target molecule. ... selection is commonly performed using filters, panning, or affinity chromatography separations. However, these ...
(Date:5/3/2016)... Chicago (PRWEB) , ... May 03, 2016 , ... ... has hired award-winning creative director Joe Ferrazano to serve in the newly created ... Ferrazano will be overseeing the agency’s creative efforts in the Chicago and LA ...
(Date:5/3/2016)... (PRWEB) , ... May 03, 2016 , ... Elizabeth Murray ... pet parrots to join her with one on her shoulder and one on her ... a parking lot because of years of mitral valve prolapse. , The valves of ...
Breaking Medicine News(10 mins):